Point72 Asset Management L.P. cut its holdings in shares of MacroGenics Inc (NASDAQ:MGNX) by 18.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 364,889 shares of the biopharmaceutical company’s stock after selling 80,683 shares during the quarter. Point72 Asset Management L.P. owned approximately 0.75% of MacroGenics worth $4,656,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Aperio Group LLC lifted its position in shares of MacroGenics by 80.4% during the second quarter. Aperio Group LLC now owns 27,955 shares of the biopharmaceutical company’s stock worth $474,000 after acquiring an additional 12,461 shares in the last quarter. Sofinnova Investments Inc. boosted its holdings in shares of MacroGenics by 5.1% in the second quarter. Sofinnova Investments Inc. now owns 550,443 shares of the biopharmaceutical company’s stock worth $9,341,000 after acquiring an additional 26,687 shares during the period. Virtus ETF Advisers LLC purchased a new position in shares of MacroGenics in the second quarter valued at $297,000. California Public Employees Retirement System grew its position in shares of MacroGenics by 546.9% in the third quarter. California Public Employees Retirement System now owns 95,102 shares of the biopharmaceutical company’s stock valued at $1,214,000 after purchasing an additional 80,400 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of MacroGenics by 5.3% in the second quarter. Vanguard Group Inc. now owns 3,198,214 shares of the biopharmaceutical company’s stock valued at $54,275,000 after purchasing an additional 161,920 shares in the last quarter. 95.99% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:MGNX opened at $9.28 on Tuesday. MacroGenics Inc has a 52-week low of $7.43 and a 52-week high of $32.32. The stock has a fifty day moving average of $9.27 and a 200 day moving average of $13.54. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.79 and a quick ratio of 4.79.

MacroGenics (NASDAQ:MGNX) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.03. MacroGenics had a negative return on equity of 59.67% and a negative net margin of 303.08%. The business had revenue of $18.74 million for the quarter, compared to analyst estimates of $23.33 million. Equities analysts predict that MacroGenics Inc will post -3.37 earnings per share for the current fiscal year.

Several brokerages have commented on MGNX. HC Wainwright cut their target price on MacroGenics from $39.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Morgan Stanley cut MacroGenics from an “equal” rating to a “weight” rating and decreased their price target for the company from $17.00 to $6.00 in a research report on Thursday, November 21st. Citigroup decreased their price target on MacroGenics from $39.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Leerink Swann lowered their price target on shares of MacroGenics from $26.00 to $18.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Finally, Wedbush cut their price objective on shares of MacroGenics from $23.00 to $14.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $23.62.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.

Featured Article: Why do corrections happen?

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.